| Related Articles |
Antithrombotic medications and recurrent miscarriage.
N Engl J Med. 2010 Aug 26;363(9):887-8; author reply 888
Authors: Visser J, Cohen D, Bloemenkamp KW
PMID: 20799392 [PubMed - in process]
[...]
|
||||||||||||||||||||
Cost consciousness and medical education. N Engl J Med. 2010 Aug 26;363(9):889-90; author reply 890-1 Authors: Robben SH, Melis RJ, Olde Rikkert MG PMID: 20799393 [PubMed - in process] [...]
Cost consciousness and medical education. N Engl J Med. 2010 Aug 26;363(9):889; author reply 890-1 Authors: Dzik W PMID: 20799394 [PubMed - in process] [...]
Cost consciousness and medical education. N Engl J Med. 2010 Aug 26;363(9):890; author reply 890-1 Authors: Azer SA PMID: 20799395 [PubMed - in process] [...]
Antithrombotic medications and recurrent miscarriage. N Engl J Med. 2010 Aug 26;363(9):887; author reply 888 Authors: Pasquier E, de Saint Martin L PMID: 20738192 [PubMed - in process] [...]
Cost consciousness and medical education. N Engl J Med. 2010 Aug 26;363(9):888-9; author reply 890-1 Authors: Rivas H, Morton JM, Krummel TM PMID: 20738193 [PubMed - in process] [...]
This week in the journal. N Engl J Med. 2010 Aug 19;363(8):710 Authors: PMID: 20718669 [PubMed - in process] [...]
Effect of valsartan on the incidence of diabetes. N Engl J Med. 2010 Aug 19;363(8):792-3 Authors: To the Editor: In their article on the valsartan portion of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial (April 22 issue),(1) McMurray et al. report a significant reduction of 14% in the relative hazard of diabetes among patients receiving valsartan, as compared with placebo. However, the investigators did not address the presence of two possibly confounding factors. First, there was a higher prevalence of the metabolic syndrome among patients assigned to placebo than among those assigned to valsartan, which could have predisposed those patients to diabetes.(2) It is unclear whether this difference was taken into . . . PMID: 20718670 [PubMed - in process] [...]
Dutasteride and prostate cancer. N Engl J Med. 2010 Aug 19;363(8):793-6 Authors: To the Editor: In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, Andriole et al. (April 1 issue)(1) found that there was a reduction in low-grade prostate cancer among high-risk men after dutasteride treatment – similar to the results with finasteride therapy among low-risk men in the Prostate Cancer Prevention Trial.(2) However, there was a slightly increased risk of high-grade tumors in the dutasteride group at the end of the study. The authors speculate that this was caused by the more frequent early detection of low-grade tumors in the placebo group. Some of these might have progressed to . . . PMID: 20718671 [PubMed - in process] [...]
Ultrasound-guided internal jugular vein cannulation. N Engl J Med. 2010 Aug 19;363(8):796-7 Authors: To the Editor: We wish that Ortega et al. (April 22 issue)(1) had demonstrated the use of the needle-guide technique in their video of internal jugular vein cannulation. As noted in the video, it can be difficult to determine the location of the tip of the needle, which may be either in front of or behind the narrow cross-sectional plane of the ultrasound image. With the use of a needle guide, the operator can direct the needle tip such that it intersects the middle of the image on the screen at the depth prescribed by the guide. This technique has . . . PMID: 20718672 [PubMed - in process] [...] |
||||||||||||||||||||
|
|
||||||||||||||||||||